🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Lake Street lifts Aquestive stock target, keeps buy on NDA submission

EditorNatashya Angelica
Published 11/06/2024, 10:09 AM
AQST
-

On Wednesday, Lake Street Capital Markets updated its outlook on shares of Aquestive Therapeutics (NASDAQ:AQST), increasing the price target to $10.00 from the previous $7.00. The firm maintained its Buy rating on the stock. The adjustment reflects anticipated milestones for the company, including the submission of the New Drug Application (NDA) for its Anaphylm product.

Aquestive Therapeutics is on track to meet significant milestones within the next five months, according to the analyst at Lake Street Capital Markets. The most critical of these milestones is the submission of the Anaphylm NDA, which is expected to be a major value driver for the company.

Prior to this submission, Aquestive will have a pre-NDA meeting and complete a pediatric study for Anaphylm, along with a pre-Investigational New Drug (IND) meeting for AQST-108.

The firm's analyst believes that the successful completion of these steps will set Aquestive up for a strong second quarter in 2025. By then, the company aims to have submitted the NDA and aligned with the FDA on the Phase 2 program for AQST-108. The analyst also notes that these developments will underscore the strategic direction taken by CEO Dan Barber since his appointment in mid-2022 and should provide reassurance to investors.

The report further highlights the potential impact of Anaphylm, suggesting that it could be transformative for patients, caregivers, physicians, as well as Aquestive and its shareholders. The analyst expresses confidence in the likelihood of a successful NDA submission and subsequent approval, stating that each step in the process should increase investor confidence in the company's prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.